Opinion | Gilead Sciences Is the Target of a Bizarre Legal Theory

A lawsuit claims Gilead should have rolled out a new drug sooner.

Get In on This Skin Disease Drug Before Big Pharma Does

What to Read Next

Big Pharma Bets Big on China

China remains attractive to global pharmaceutical companies, even as many multinationals are turning their attention elsewhere.

WSJ News Exclusive | Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion

RoiEvent, launched by presidential candidate Vivek Ramaswamy, may seal a deal in the coming days.

WSJ News Exclusive | Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion

RoiEvent, launched by presidential candidate Vivek Ramaswamy, may seal a deal in the coming days.

Obesity Drugs Won’t Starve These Other Potential Blockbusters

Shares of developers of fatty liver disease treatments were in decline until Eli Lilly published results…

New Gene Therapy Could Face Uphill Battle

The FDA’s potential approval of BioMarin’s gene therapy for hemophilia A would be a major win,…

New Gene Therapy Could Face Uphill Battle

The FDA’s potential approval of BioMarin’s gene therapy for hemophilia would be a major win, but…

The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million

The drug, from Sarepta Therapeutics, holds promise for correcting the faulty gene at the root of…

Even Mark Cuban Can’t Fix This Broken Drug System

Coherus Biosciences’ partnership to offer the deeply discounted biosimilar Humira could only go further in driving…